Evidence map›Paper›PMID 32823610›Full record

ArticleInternational journal of molecular sciences2020

EphrinA1-Fc Attenuates Ventricular Remodeling and Dysfunction in Chronically Nonreperfused WT but not EphA2-R-M mice.

K'Shylah S Whitehurst, Victoria A Chan, Heather K Estes, Smrithi Valsaraj, Susan Kent, Uma M Sharma, R Christopher Chase, Maliha Bhuiyan, Jitka A I Virag

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Guidelines for in vivo mouse models of myocardial infarction.American journal of physiology. Heart and circulatory physiology · 2021
    Guideline
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

K'Shylah S WhitehurstDepartment of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA.
Victoria A ChanDepartment of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA.
Heather K EstesDepartment of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA.
Smrithi ValsarajDepartment of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA.
Susan KentDepartment of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA.
Uma M SharmaDepartment of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA.
R Christopher ChaseDepartment of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA.
Maliha BhuiyanDepartment of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA.
Jitka A I ViragDepartment of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA.ORCID 0000-0003-3321-9861
East Carolina University · US

Funding

Salvaging the ischemic myocardium: the role ephrinA1/EphA bidirectional signalingR15HL124483 · NHLBI · EAST CAROLINA UNIVERSITY · PI VIRAG, JITKA A.I. · 2015 to 2015
$443k
NHLBI NIH HHS 1RH15HL124483-01A1
6 · The paper itself

Abstract

backgroundEphrinA1-Fc abolishes acute I/R injury and attenuates nonreperfused cardiac injury 4 days after permanent occlusion in mice. The goal of this study was to assess the capacity of a single intramyocardial administration of ephrinA1-Fc at the time of coronary artery ligation, to determine the degree to which early salvage effects translate to reduced adverse remodeling after 4 weeks of nonreperfused myocardial infarction (MI) in wild-type B6 and EphA2-R-M (EphA2 receptor null) mice.

methodsAt 4 weeks post-MI, echocardiography, histologic and immunohistochemical analyses of B6 mouse hearts were performed. Primary mouse cardiac fibroblasts (FBs) isolated from B6 mice cultured in the presence of low and high dose ephrinA1-Fc, both with and without pro-fibrotic TGF-β stimulation and Western blots, were probed for relative expression of remodeling proteins MMP-2, MMP-9 and TIMP-1, in addition to DDR2 and (p)SMAD2/3/totalSMAD2/3.

resultsEphrinA1-Fc preserved a significant degree of contractile function, decreased adverse left ventricular remodeling, attenuated excessive compensatory hypertrophy, and decreased interstitial fibrosis in wild-type (WT) B6 mouse hearts. In contrast, most of these parameters were poorer in ephrinA1-Fc-treated EphA2-R-M mice. Of note, fibrosis was proportionately decreased, implying that other EphA receptor(s) are more important in regulating the pro-fibrotic response. Primary FBs showed disparate alteration of MMP-2, MMP-9 and TIMP-1, as well as DDR2 and p-SMAD2/3/totalSMAD2/3, which indicates that matrix remodeling and cardiac fibrosis in the injured heart are influenced by ephrinA1-Fc.

conclusionThis study demonstrates the capacity of a single administration of ephrinA1-Fc at the onset of injury to attenuate long-term nonreperfused post-MI ventricular remodeling that results in progressive heart failure, and the important role of EphA2 in mitigating the deleterious effects.

Indexed as

ReperfusionVentricular RemodelingActinsAnimalsCells, CulturedEphrin-A1FibrosisHeartImmunoglobulin Fc FragmentsKaplan-Meier EstimateMice, TransgenicMyocardial InfarctionMyocytes, CardiacMyofibroblastsReceptor, EphA2ActinsEphrin-A1Immunoglobulin Fc FragmentsReceptor, EphA2EphA2ephrinA1fibrosismyocardial infarctionremodeling

Identifiers

PMID32823610
PMCPMC7461052
OpenAlexW3048397001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.